Efficacy and safety of posaconazole for the prevention of invasive fungal disease in childhood acute leukemia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200064677

Enrollment

Unknown

Registered

2022-10-14

Start date

2022-10-13

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive fungal disease

Interventions

Intervention group:Posaconazole

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Age 0-18 years; 2. Patients with a diagnosis of acute leukemia; 3. Patients with neutrophil deficiency due to induction chemotherapy and other treatment regimens, to be treated with posaconazole.

Exclusion criteria

Exclusion criteria: 1. Patients with invasive fungal disease at baseline; 2. Undergoing systemic antifungal therapy within the last 14 days; 3. Hypersensitivity to posaconazole.

Design outcomes

Primary

Measure	Time frame
Incidence of invasive fungal disease;Success rate of plasma concentration of Posaconazole;	—

Countries

China

Contacts

Public ContactZhang Ruidong

Beijing Children's Hospital, Capital Medical University

zhangruidong@vip.sina.com+86 13801265377

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026